248 related articles for article (PubMed ID: 12970268)
1. Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia.
Nelson AE; Bligh RC; Mirams M; Gill A; Au A; Clarkson A; Jüppner H; Ruff S; Stalley P; Scolyer RA; Robinson BG; Mason RS; Bligh PC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4088-94. PubMed ID: 12970268
[TBL] [Abstract][Full Text] [Related]
2. Effects of tumor-induced osteomalacia on the bone mineralization process.
Nawrot-Wawrzyniak K; Varga F; Nader A; Roschger P; Sieghart S; Zwettler E; Roetzer KM; Lang S; Weinkamer R; Klaushofer K; Fratzl-Zelman N
Calcif Tissue Int; 2009 Apr; 84(4):313-23. PubMed ID: 19219382
[TBL] [Abstract][Full Text] [Related]
3. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
4. Intracranial phosphaturic mesenchymal tumors. A case report and review of literature.
Kojima D; Ohba S; Abe M; Suzuki A; Horibe S; Tateya I; Hasegawa M; Hirose Y
Neuropathology; 2022 Oct; 42(5):453-458. PubMed ID: 35880350
[TBL] [Abstract][Full Text] [Related]
5. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia.
Bahrami A; Weiss SW; Montgomery E; Horvai AE; Jin L; Inwards CY; Folpe AL
Am J Surg Pathol; 2009 Sep; 33(9):1348-54. PubMed ID: 19609206
[TBL] [Abstract][Full Text] [Related]
6. Bone as a source of FGF23: regulation by phosphate?
Mirams M; Robinson BG; Mason RS; Nelson AE
Bone; 2004 Nov; 35(5):1192-9. PubMed ID: 15542045
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
Hannan FM; Athanasou NA; Teh J; Gibbons CL; Shine B; Thakker RV
Eur J Endocrinol; 2008 Feb; 158(2):265-71. PubMed ID: 18230836
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia.
Fukumoto S; Takeuchi Y; Nagano A; Fujita T
Bone; 1999 Sep; 25(3):375-7. PubMed ID: 10495143
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.
Leaf DE; Pereira RC; Bazari H; Jüppner H
J Clin Endocrinol Metab; 2013 Mar; 98(3):887-91. PubMed ID: 23393166
[TBL] [Abstract][Full Text] [Related]
11. Occult nasal sinus tumours causing oncogenic osteomalacia.
Kenealy H; Holdaway I; Grey A
Eur J Intern Med; 2008 Nov; 19(7):516-9. PubMed ID: 19013380
[TBL] [Abstract][Full Text] [Related]
12. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors.
Carter JM; Caron BL; Dogan A; Folpe AL
Am J Surg Pathol; 2015 Jan; 39(1):75-83. PubMed ID: 25025444
[TBL] [Abstract][Full Text] [Related]
13. Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia.
Westerberg PA; Olauson H; Toss G; Wikström B; Morales O; Linde T; Jonsson K; Ljunggren O; Larsson TE
Endocr Pract; 2008 Apr; 14(3):362-7. PubMed ID: 18463045
[TBL] [Abstract][Full Text] [Related]
14. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.
Rowe PS; de Zoysa PA; Dong R; Wang HR; White KE; Econs MJ; Oudet CL
Genomics; 2000 Jul; 67(1):54-68. PubMed ID: 10945470
[TBL] [Abstract][Full Text] [Related]
15. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors.
Carpenter TO; Ellis BK; Insogna KL; Philbrick WM; Sterpka J; Shimkets R
J Clin Endocrinol Metab; 2005 Feb; 90(2):1012-20. PubMed ID: 15562028
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587
[TBL] [Abstract][Full Text] [Related]
18. [Chronic bone pain due to raised FGF23 production? The importance of determining phosphate levels].
de Jongh RT; Vervloet MG; Bravenboer N; Heijboer AC; den Heijer M; Lips P
Ned Tijdschr Geneeskd; 2013; 157(28):A5908. PubMed ID: 23841927
[TBL] [Abstract][Full Text] [Related]
19. Phosphaturic mesenchymal tumor, nonphosphaturic variant, causing fatal pulmonary metastasis.
Uchihashi K; Nishijima-Matsunobu A; Matsuyama A; Yamasaki F; Tanabe T; Uemura T; Aragane N; Yakushiji M; Yamamoto M; Aoki S; Toda S
Hum Pathol; 2013 Nov; 44(11):2614-8. PubMed ID: 23954138
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case.
Dupond JL; Mahammedi H; Prié D; Collin F; Gil H; Blagosklonov O; Ricbourg B; Meaux-Ruault N; Kantelip B
Bone; 2005 Mar; 36(3):375-8. PubMed ID: 15777669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
